The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
